Assessment of Bone Mineral Density Over 1 Year in a Cross-Sectional Cohort of Migraine Patients Receiving Anti-CGRP Monoclonal Antibodies.
Davide ParaChiara CamponovoGianna Carla RiccitelliGiulia MallucciPaolo MainoCamilla Mondini Trissino da LodiDemurtas SaudinaPierpaolo TrimboliClaudio GobbiChiara ZeccaPublished in: CNS drugs (2024)
In our cohort of migraine patients, no evidence of an association between anti-CGRP treatment duration and an increasing risk of bone mineral density abnormalities was found. However, these findings are preliminary and necessitate further longitudinal research with larger cohorts and extended follow-up to be validated.